CMA Decline Drives Age-Related Skeletal Muscle Myopathy

Skeletal muscle must continually maintain its protein and organelle quality to preserve force and metabolic function. In this study of age-related chaperone-mediated autophagy (CMA) decline, the authors identify CMA as an active contributor to muscle homeostasis, rather than simply a pathway that changes alongside ageing. Their findings connect reduced CMA to progressive myopathy, altered calcium regulation, and changes in the mitochondrial proteome.

Study Background and Research Question

Muscle mass and performance depend on a balance between protein synthesis and degradation. In catabolic conditions, increased breakdown can contribute to wasting, with both the ubiquitin–proteasome system and autophagy–lysosomal pathways involved in removing cellular material. Macroautophagy, which delivers cargo to lysosomes in autophagosomes, has a well-established role in muscle physiology. By comparison, the contribution of CMA to skeletal muscle function has been less clear.

CMA differs from macroautophagy: proteins bearing a KFERQ-like recognition motif are bound by the chaperone HSC70 and transported across the lysosomal membrane through LAMP2A. Because LAMP2A is rate-limiting for this process, lower LAMP2A availability can reduce CMA capacity. Previous observations of reduced CMA activity in aged mouse muscle prompted the central questions here: when does muscle CMA change, what happens when muscle CMA is lost, and can increasing it mitigate age-associated dysfunction?

Key Innovation from the Reference Study

The study’s central advance is its combination of activity measurements, muscle-specific genetic loss of CMA, molecular analysis, and an ageing intervention. This strategy moves beyond measuring age-related expression changes: it tests whether CMA is required for muscle integrity and investigates a molecular route by which its loss could affect contractile function.

A notable mechanistic finding is the identification of sarcoplasmic–endoplasmic reticulum Ca²⁺-ATPase (SERCA) as a CMA substrate. SERCA helps maintain intracellular calcium stores, which are essential for muscle contraction and relaxation. The authors associate impaired SERCA turnover in CMA-deficient muscle with abnormal calcium storage and dysregulated calcium dynamics. The results therefore connect selective lysosomal protein turnover to a functionally important aspect of muscle physiology.

Methods and Experimental Design Insights

To monitor CMA in vivo, the researchers used mice expressing KFERQ-Dendra2, a fluorescent reporter containing a CMA-recognition motif. Reporter puncta indicate delivery to lysosomes through CMA. Tissue sections were also stained for LAMP1, an endolysosomal marker, enabling the team to consider CMA-competent lysosomes in relation to the broader lysosome population. Quantification per myofibre area helped account for differences in tissue structure and cellular dimensions.

The study assessed CMA under physiological and pathological conditions, including starvation, exercise, tissue repair, ageing, and obesity. For causal testing, the researchers generated a muscle-specific Lamp2a knockout model, HSA-Cre:L2A^fl/fl (HSAL2A^−/−). This approach asks what happens when muscle CMA is impaired, while reducing the likelihood that observed muscle phenotypes arise only from a whole-body loss of LAMP2A. Comparative proteomic analyses then helped identify protein-level changes associated with CMA deficiency. Finally, the team tested genetic upregulation of CMA in old mice and assessed whether this intervention could improve ageing-related muscle features.

These methods offer a useful design principle for proteostasis research: pair a pathway-activity readout with a targeted perturbation and functional outcomes. Reporter puncta provide an in-tissue activity proxy, while genetic loss and proteomic analysis address necessity and potential substrates. No single readout establishes the complete mechanism, so the value comes from interpreting these complementary measurements together.

Protocol Parameters

• Starvation challenge: The study examined 24 h and 48 h of starvation in six-month-old KFERQ-Dendra2 mice; these are reported experimental conditions, not a universal recommendation for other models.
• CMA reporter analysis: Quantify KFERQ-Dendra2 puncta in muscle sections and interpret them alongside LAMP1 staining, as in the reference study.
• Muscle-specific CMA loss: The reported genetic model used HSA-Cre-mediated Lamp2a deletion; genotype, tissue specificity, and appropriate control animals should be verified for any replication.
• Functional interpretation: Pair pathway and protein measurements with muscle-force and calcium-handling outcomes where the research question concerns contractile function.

Core Findings and Why They Matter

The study reports that muscle CMA responds to changing physiological demands. Starvation increased CMA reporter activity, with a more pronounced increase in females in the tested mouse cohort. The response involved a greater proportion of lysosomes becoming CMA-competent; total endolysosome number did not increase in males and decreased in females. The authors also report CMA upregulation in response to exercise and tissue repair, whereas ageing and obesity were associated with lower activity. Together, these observations suggest that muscle CMA is regulated by both demand and metabolic state, rather than being a static housekeeping process.

The muscle-specific knockout provides evidence that CMA is important for tissue maintenance. Loss of muscle CMA led to progressive myopathy, including reduced force and degenerative myofibre features. This matters because age-related declines in protein quality control could have consequences beyond altered protein abundance: they may erode the structural and functional integrity of fibres over time.

Proteomic and mechanistic analyses further point to mitochondrial protein changes and impaired SERCA turnover. The proposed connection between SERCA dysregulation and disturbed calcium storage offers a plausible explanation for how selective protein-clearance defects may affect muscle performance. It also broadens the interpretation of autophagy in muscle: lysosomal degradation can influence the handling of individual proteins with direct roles in calcium homeostasis, not only bulk removal of damaged cellular material.

The authors also report reduced CMA in aged human skeletal muscle, supporting the relevance of the mouse findings to human ageing. This human observation is an association and does not, on its own, establish that reduced CMA causes human muscle decline. In old mice, genetic upregulation of CMA partially ameliorated skeletal-muscle ageing phenotypes. The partial nature of the improvement is important: CMA is a promising mechanistic contributor, not a demonstrated single explanation or complete reversal of muscle ageing.

Comparison with Existing Internal Articles

The reference study focuses on CMA and lysosomal protein translocation; it does not test proteasome inhibition. This distinction is useful when comparing it with internal resources such as MG-262 applied proteasome inhibition workflows and precision proteasome inhibition workflows. Those articles address perturbation of proteasome activity, including experimental questions related to ubiquitin-dependent turnover, apoptosis research, and cell-cycle studies. They complement the CMA paper as resources on a different arm of proteostasis, but they should not be read as evidence that MG-262 was used in, or reproduces, the CMA experiments.

Why this cross-domain matters, maturity, and limitations

Muscle proteostasis involves both autophagy–lysosomal degradation and the ubiquitin–proteasome system, but these pathways are not interchangeable. The reference study’s evidence concerns CMA, LAMP2A, and lysosomal handling of substrates such as SERCA. Proteasome inhibition can be useful for asking separate questions about proteasomal turnover or ubiquitinated-protein accumulation; it cannot, by itself, establish CMA activity or validate SERCA as a CMA substrate. The connection is therefore experimental context, not a shared mechanism demonstrated by this paper.

This distinction also helps with study design. A proteasome inhibition assay may be appropriate when testing proteasome-dependent protein degradation, while CMA claims require CMA-relevant readouts and perturbations. Combining pathway interventions can be informative only when each pathway is measured independently and the interpretation accounts for possible compensatory responses. The paper establishes a strong mouse-model rationale for studying CMA in muscle and provides supportive human age-associated data, but it does not establish that the same intervention will have equivalent effects in people.

Limitations and Transferability

Several considerations shape how broadly the findings can be applied. First, fluorescent reporter puncta are a proxy for CMA-related lysosomal delivery, not a complete measurement of the degradation rate of every endogenous substrate. Second, a muscle-specific knockout can reveal consequences of CMA loss in muscle, but the severity and timing of its phenotype may differ from the gradual decline that occurs during natural ageing. Third, the human finding supports clinical relevance but does not prove causation or show that increasing CMA is safe or effective in people.

The rescue experiment is encouraging but partial, and further work is needed to determine which muscle functions are most responsive and how durable the benefit is. The reported association between SERCA handling and calcium dysregulation is mechanistically informative, but it should not be generalized to every age-related muscle phenotype. These boundaries do not diminish the paper’s contribution; they clarify that CMA is an important component of muscle maintenance while leaving room for other pathways and disease-specific factors.

Research Support Resources

For experiments that separately examine proteasome-dependent turnover alongside CMA biology, researchers can use MG-262 (Z-Leu-Leu-Leu-B(OH)2) (SKU A8179), a reversible, cell-permeable proteasome inhibitor. It is a tool for proteasome perturbation, not a CMA-specific reagent, so pathway-specific controls and readouts remain essential.